Last reviewed · How we verify
rituximab, ifosfamide, carboplatin, and etoposide phosphate
rituximab, ifosfamide, carboplatin, and etoposide phosphate is a Small molecule drug developed by Genmab. It is currently in Phase 1 development. Also known as: R-ICE.
At a glance
| Generic name | rituximab, ifosfamide, carboplatin, and etoposide phosphate |
|---|---|
| Also known as | R-ICE |
| Sponsor | Genmab |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Pyrexia
- Anaemia
- Nausea
- Neutropenia
- Diarrhoea
- Infection
- Fatigue
- Headache
- Hypotension
- Pneumonia
- Thrombocytopenia
- Hypokalaemia
Key clinical trials
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (PHASE1, PHASE2)
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (PHASE1, PHASE2)
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (PHASE2, PHASE3)
- A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (PHASE3)
- Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma (PHASE1)
- Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma (PHASE3)
- A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rituximab, ifosfamide, carboplatin, and etoposide phosphate CI brief — competitive landscape report
- rituximab, ifosfamide, carboplatin, and etoposide phosphate updates RSS · CI watch RSS
- Genmab portfolio CI
Frequently asked questions about rituximab, ifosfamide, carboplatin, and etoposide phosphate
What is rituximab, ifosfamide, carboplatin, and etoposide phosphate?
rituximab, ifosfamide, carboplatin, and etoposide phosphate is a Small molecule drug developed by Genmab.
Who makes rituximab, ifosfamide, carboplatin, and etoposide phosphate?
rituximab, ifosfamide, carboplatin, and etoposide phosphate is developed by Genmab (see full Genmab pipeline at /company/genmab).
Is rituximab, ifosfamide, carboplatin, and etoposide phosphate also known as anything else?
rituximab, ifosfamide, carboplatin, and etoposide phosphate is also known as R-ICE.
What development phase is rituximab, ifosfamide, carboplatin, and etoposide phosphate in?
rituximab, ifosfamide, carboplatin, and etoposide phosphate is in Phase 1.
What are the side effects of rituximab, ifosfamide, carboplatin, and etoposide phosphate?
Common side effects of rituximab, ifosfamide, carboplatin, and etoposide phosphate include Pyrexia, Anaemia, Nausea, Neutropenia, Diarrhoea, Infection.
Related
- Manufacturer: Genmab — full pipeline
- Also known as: R-ICE
- Compare: rituximab, ifosfamide, carboplatin, and etoposide phosphate vs similar drugs
- Pricing: rituximab, ifosfamide, carboplatin, and etoposide phosphate cost, discount & access